For the Inventor, By the Inventor

Enter assignee name

Tübingen, Germany

Curevac Se

USPTO Granted Patents = 56

CIPO Patents = 3

EPO Patents = 8

Trademarks = 12

Forward Citations = 126

Loading Chart...

Loading Chart...

63 inventors (with patents filed for the assignee):

Benjamin Petsch (26 out of 42 patents)

Susanne Rauch (14 out of 19 patents)

Thomas Kramps (12 out of 25 patents)

4. Margit Schnee (10 out of 21 patents)

5. Tilmann Roos (8 out of 18 patents)

6. Thomas Schlake (8 out of 32 patents)

7. Karl-Josef Kallen (8 out of 29 patents)

8. Hans Wolfgang Große (8 out of 11 patents)

9. Edith Jasny (7 out of 8 patents)

10. Benyamin Yazdan Panah (6 out of 14 patents)

11. Andreas Thess (6 out of 66 patents)

12. Daniel Voss (6 out of 11 patents)

13. Mariola Fotin-Mleczek (6 out of 26 patents)

14. Lothar Stitz (5 out of 11 patents)

15. Jochen Probst (5 out of 37 patents)

Core Competencies:

Artificial Nucleic Acid Molecules

RNA Vaccine

CRISPR-Associated Proteins

Combination Vaccine

Respiratory Syncytial Virus Vaccine

Coronavirus Vaccine

Vaccination in Newborns

Long-Chain RNA

Peptide Expression

Viral Vaccines

mRNA-Coded Antigens

Polymeric Carrier Cargo Complex

56 patents: Sort by Forward Citations

1. 12460204 - Artificial nucleic acid molecules for improved protein or peptide expression (2025-11-04),

2. 12447209 - Combination of vaccination and inhibition of the PD-1 pathway (2025-10-21),

3. 12442005 - Artificial nucleic acid molecules for improved protein expression (2025-10-14),

4. 12397048 - Bunyavirales vaccine (2025-08-26),

5. 12390523 - Coronavirus vaccine (2025-08-19),

6. 12390520 - Vaccination in newborns and infants (2025-08-19),

7. 12385088 - Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA (2025-08-12),

8. 12371699 - Nucleic acids encoding CRISPR-associated proteins and uses thereof (2025-07-29),

9. 12350330 - RSV RNA molecules and compositions for vaccination (2025-07-08),

10. 12337031 - Combination vaccine (2025-06-24),

11. 12318486 - Dry powder composition comprising long-chain RNA (2025-06-03),

12. 12318444 - Rotavirus vaccines (2025-06-03),

13. 12258567 - Artificial nucleic acid molecules (2025-03-25),

14. 12240873 - Respiratory syncytial virus (RSV) vaccine (2025-03-04),

15. 12227549 - RNA encoding a therapeutic protein (2025-02-18),

CureVac is a leading clinical-stage bio-pharmaceutical company that focuses on developing mRNA-based therapies and vaccines. They leverage their cutting-edge messenger RNA (mRNA) technology platform to develop innovative solutions for various diseases, including infectious diseases, cancer, and rare diseases. CureVac's mRNA technology enables them to potentially create personalized medicines and combat emerging pandemic threats, offering a promising approach to healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

56 Patents

#2 in Tübingen

#989 in Germany

#12,337 in the World

Tübingen, Germany

Curevac Se

Forward Citations = 126

63 inventors:

Benjamin Petsch (26 out of 42 patents)

Susanne Rauch (14 out of 19 patents)

Thomas Kramps (12 out of 25 patents)

4. Margit Schnee (10 out of 21 patents)

5. Tilmann Roos (8 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…